Search Results - "Viel, Kevin R"

Response to 'Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome' by Viel, Kevin R

Get full text

Inhibitors of Factor VIII in Black Patients with Hemophilia by Viel, Kevin R, Ameri, Afshin, Abshire, Thomas C, Iyer, Rathi V, Watts, Raymond G, Lutcher, Charles, Channell, Cynthia, Cole, Shelley A, Fernstrom, Karl M, Nakaya, Shelley, Kasper, Carol K, Thompson, Arthur R, Almasy, Laura, Howard, Tom E

“…Black patients with hemophilia are more likely to form antibodies against replacement factor VIII than are white patients. This article suggests a mechanism…”
Get full text

Endogenous factor VIII synthesis from the intron 22–inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A by Pandey, Gouri Shankar, Yanover, Chen, Miller-Jenkins, Lisa M, Garfield, Susan, Cole, Shelley A, Curran, Joanne E, Moses, Eric K, Rydz, Natalia, Simhadri, Vijaya, Kimchi-Sarfaty, Chava, Lillicrap, David, Viel, Kevin R, Przytycka, Teresa M, Pierce, Glenn F, Howard, Tom E, Sauna, Zuben E

“…Patients with hemophilia lacking functional coagulation factor VIII (FVIII) are treated with replacement FVIII proteins. The development of neutralizing…”
Get full text

A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels by Viel, Kevin R., Machiah, Deepa K., Warren, Diane M., Khachidze, Manana, Buil, Alfonso, Fernstrom, Karl, Souto, Juan C., Peralta, Juan M., Smith, Todd, Blangero, John, Porter, Sandra, Warren, Stephen T., Fontcuberta, Jordi, Soria, Jose M., Dana Flanders, W., Almasy, Laura, Howard, Tom E.

“…Plasma factor VIII coagulant activity (FVIII:C) level is a highly heritable quantitative trait that is strongly correlated with thrombosis risk. Polymorphisms…”
Get full text

Dissection of heterogeneous phenotypes for quantitative trait mapping by Bickeböller, Heike, Bailey, Julia N., Papanicolaou, George J., Rosenberger, Albert, Viel, Kevin R.

“…We discuss analyses of Genetic Analysis Workshop 14 data from the Collaborative Study on the Genetics of Alcoholism (COGA) as well as from a simulated complex…”
Get full text

Gene-Centric Association Scans of Pleiotropic Immune-Mediated Disease Genes in the PATH Study Identify Novel Determinants of Factor VIII Inhibitor Risk in Hemophilia-A Patients and Confirm Race as an Independent Predictor by Bouls, Ruayda, Almeida, Marcio A., Diego, Vincent P., Luu, Bernadette W., Rajalingam, Raja, Ameri, Afshin, Viel, Kevin R., Chitlur, Meera, Kim, Benjamin, Escobar, Miguel A., Williams-Blangero, Sarah, Kasper, Carol K., Almasy, Laura, Blangero, John, Howard, Tom E.

“…Hemophilia-A (HA) is caused by heterogeneous loss-of-function factor (F) VIII gene ( F8) mutations and deficiencies in plasma FVIII coagulant activity…”
Get full text

Results from an Association-Scan of the Extended MHC-Class-II Region Using Novel Association-Based Statistical Methods Establish That DQ Allotypes and Race Independently Influence the Risk of Factor VIII Inhibitor Development in Hemophilia-A Patients by Ibarra, Paola, Almeida, Marcio A., Diego, Vincent P., Luu, Bernadette W., Viel, Kevin R., Rajalingam, Raja, Ameri, Afshin, Chitlur, Meera, Kim, Benjamin, Castillo, Grecia, Powell, Jerry S., Peralta, Juan M., Escobar, Miguel A., Williams-Blangero, Sarah, Blangero, John, Kasper, Carol K., Almasy, Laura, Howard, Tom E.

“…Hemophilia-A (HA) is caused by heterogeneous factor (F) VIII gene ( F8) mutations, variably deficient plasma FVIII activity and reduced to absent…”
Get full text

A Novel Biomarker for Inhibitor Risk Prediction-the HLA-II Bound and Unbound Components of FVIII Derived Peptides-Reveals a Protective Influence for N-Linked Glycosylation by Viel, Kevin R., Hofmann, Marco, Zollner, Sabine, Luu, Bernadette W., Raja, Rajalingam, Powell, Jerry Sherman, Maraskovsky, Eugene, Howard, Tom E.

“…Introduction: Factor (F)VIII immunogenicity is the main obstacle to both successfully treating hemophilia and receiving FDA approval for new therapeutics…”
Get full text

The Spectrum of Amino Acid Substitutions Resulting from Single Nucleotide Substitutions in the Coagulation Biosystem: Impact on Identification By Mass Spectrometry by Viel, Kevin R., Kim, Benjamin, Tejero, Maria Elizabeth, Cole, Shelley S., Howard, Tom E., Ortiz, Amparo Santamaría

“…INTRODUCTION Mass spectrometry (MS) is a potentially useful tool for the study of the hemostasic system and its imbalances that lead to bleeding and thrombotic…”
Get full text

F8 and HLA-II Haplotypes in the Hispanic Population: Implications for Inhibitor Risk Development in Hispanic Hemophilia A Patients by Kim, Benjamin, Sauna, Zuben E., Carless, Melanie A., Curran, Joanne E., Viel, Kevin R., Cole, Shelley S., Raja, Rajalingam, Blangero, John, Howard, Tom E.

“…Abstract 3365 A recent study suggested an increased rate of inhibitor development among Hispanic compared to White hemophilia A (HA) patients; however, a…”
Get full text

Common SNPs within or near Three Immune Response Genes Implicated in the Risk of FVIII Immunogenicity in Hemophilia A Do Not Influence Steady-State Levels of Their Encoded mRNAs by Howard, Tom E., Drigalenko, Eugene, Johnson, Matthew P., Cole, Shelley S., Kim, Benjamin, Viel, Kevin R., Sauna, Zuben E., Curran, Joanne E., Blangero, John, Almasy, Laura A., Göring, Harald H.

“…Abstract 3366 The hemophilia A (HA)-causing Factor (F)VIII gene (F8) mutation type is a well-established determinant of risk for the development of alloimmune…”
Get full text

Haemophilia management: time to get personal? by HOWARD, T. E., YANOVER, C., MAHLANGU, J., KRAUSE, A., VIEL, K. R., KASPER, C. K., PRATT, K. P.

“…The possibility of alloimmunization in patients receiving protein replacement therapy depends on (at least) three risk factors, which are necessary…”
Get full text

No Evidence of Cis-Acting SNPs In Immune Response Genes Previously Associated with Factor VIII Inhibitors: The San Antonio Family Heart Study by Howard, Tom E., Viel, Kevin R., Drigalenko, Eugene, Cole, Shelley, Epstein, Melinda, Carless, Melanie, Hughes, Richard, Kim, Benjamin, Dyer, Tom, Pratt, Kathleen P., MacCluer, Jean W., Curran, Joanne E., Johnson, Matthew P., Moses, Eric K., Blangero, John, Almasy, Laura, Göring, Harald

“…Abstract 4422 FVIII gene (F8) mutation type is a risk factor for FVIII inhibitors, which develop in ~20-30% of hemophilia A patients following FVIII…”
Get full text

Heritability of Commonly Measured Blood Cell Phenotypes in the San Antonio Family Heart Study by Viel, Kevin R., Howard, Tom, Curran, Joanne E., Almasy, Laura, Moses, Eric K., Glahn, David C., Ameri, Afshin, John, Blangero

“…Heritability (h2) indicates the extent to which genes contribute to the observed inter-individual variation in a phenotype. Traits that have a high h2 may be…”
Get full text

Potential Spectrum of Missense and Nonsense Factor (F)VIII Gene (F8) Alleles Based on Single Nucleotide Substitutions - How Many Remain To Be Identified? by Viel, Kevin R., Khachidze, Manana, Almasy, Laura, Thompson, Arthur R., Howard, Tom E.

“…Regardless of advances in prenatal diagnosis, carrier detection and gene therapy for hemophilia-A, new patients with bleeding diatheses due to inadequate…”
Get full text

Inhibitors of Factor VIII in Hemophilia by Lacroix-Desmazes, Sebastien, Dimitrov, Jordan D, Repesse, Yohann

“…To the Editor: Viel et al. (April 16 issue) 1 propose that treatment of hemophilia A with factor VIII that is matched for polymorphic variants may reduce the…”
Get full text

Allelically Mismatched Replacement Therapy Due to Common African−Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia−A Patients of African−Descent by Howard, Tom E., Viel, Kevin R., Fernstrom, Karl M., Deshpande, Seema, Ameri, Afshin, Ali, M. Showkat, Channell, Cynthia, Iyer, Rathi V., Watts, Raymond G., Lutcher, Charles, Nakaya, Shelley, Kasper, Carol K., Thompson, Arthur R., Abshire, Thomas C., Almasy, Laura

“…Alloantibodies that inhibit the function of wildtype (wt) FVIII molecules constitute the most serious complication of replacement therapy for hemophilia (H)A…”
Get full text

The Pharmacogenetics and Inhibitor Risk (PIR) Study: Establishing the Spectrum of Factor (F)VIII Gene (F8) Mutations in African-American Hemophilia A Patients by Howard, Tom E., Machiah, Deepa K., Viel, Kevin R., Channel, Cynthia, Ameri, Afshin, Iyer, Rathi V., Watts, Ray G., Lutcher, Charles, Davis, Joanna, Abshire, Thomas C., Almasy, Laura

“…The development of neutralizing antibodies against plasma-derived or recombinant (r) molecules of wildtype (wt) factor (F)VIII protein is the most serious…”
Get full text

A Quantitative Trait Locus for Cholesterol/Low Density Lipoprotein within the Promoter of the Factor IX Gene by Viel, Kevin R., Khachidze, Manana, Buil, Alfonso, Soria, José Manuel, Souto, Juan Carlos, Fontcuberta, Jordi, Blanco-Vaca, Francisco, Ordoñez-Llanos, Jordi, Almasy, Laura, Tom, Howard

“…The correlation between vitamin K-dependent coagulation factors (CF) and lipids has been previously established, with Factor VII notably receiving attention in…”
Get full text

African-Americans Express Multiple Haplotypic Forms of the Wildtype Factor VIII (FVIII) Protein: A Possible Role for Pharmacogenetics in FVIII Inhibitor Development? by Howard, Tom, Machiah, Deepa M., Tran, Thuy T., Viel, Kevin R., Channell, Cynthia, Soria, Jose Manuel, Ameri, Afshin, Iyer, Rathi V., Brown, Cara, Doering, Christopher, Almasy, Laura, Watts, Ray, Davis, Joanna, Abshire, Thomas C.

“…Recombinant factor VIII (r-fVIII) is the most widely-used and effective therapy for hemophilia A (hA). Many patients unfortunately become refractory when the…”
Get full text